Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

ZUMA‐1 (NCT02348216) examined the safety and efficacy of axicabtagene ciloleucel (axi‐cel), an autologous CD19‐directed chimaeric antigen receptor (CAR)‐T cell therapy, in refractory large B‐cell lymphoma. To reduce treatment‐related toxicity, several exploratory safety management cohorts were added...

Descripción completa

Detalles Bibliográficos
Autores principales: Oluwole, Olalekan O., Bouabdallah, Krimo, Muñoz, Javier, De Guibert, Sophie, Vose, Julie M., Bartlett, Nancy L., Lin, Yi, Deol, Abhinav, McSweeney, Peter A., Goy, Andre H., Kersten, Marie José, Jacobson, Caron A., Farooq, Umar, Minnema, Monique C., Thieblemont, Catherine, Timmerman, John M., Stiff, Patrick, Avivi, Irit, Tzachanis, Dimitrios, Kim, Jenny J., Bashir, Zahid, McLeroy, Jeff, Zheng, Yan, Rossi, John M., Johnson, Lisa, Goyal, Lovely, van Meerten, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Haematological malignancy – Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457222/
https://www.ncbi.nlm.nih.gov/pubmed/34296427
http://dx.doi.org/10.1111/bjh.17527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457222/
https://www.ncbi.nlm.nih.gov/pubmed/34296427
http://dx.doi.org/10.1111/bjh.17527

Ejemplares similares